Cargando…
Efficacy and safety of Xinnaoning capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
BACKGROUND: Chronic stable angina (CSA) is a cardiovascular disease with high prevalence. At present, drug treatment is still the main measure of stable angina pectoris. Traditional Chinese medicine has a long history in the treatment of CSA. Qi stagnation and Blood stasis syndrome is a common syndr...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709279/ https://www.ncbi.nlm.nih.gov/pubmed/31374015 http://dx.doi.org/10.1097/MD.0000000000016539 |
_version_ | 1783446173611196416 |
---|---|
author | Zhao, Jun-Nan Zhang, Ying Lan, Xu Chen, Yao Li, Jing Zhang, Ping Wu, Li-Qi Jia, Shu-Ting Liu, Yue Xu, Feng-Qin |
author_facet | Zhao, Jun-Nan Zhang, Ying Lan, Xu Chen, Yao Li, Jing Zhang, Ping Wu, Li-Qi Jia, Shu-Ting Liu, Yue Xu, Feng-Qin |
author_sort | Zhao, Jun-Nan |
collection | PubMed |
description | BACKGROUND: Chronic stable angina (CSA) is a cardiovascular disease with high prevalence. At present, drug treatment is still the main measure of stable angina pectoris. Traditional Chinese medicine has a long history in the treatment of CSA. Qi stagnation and Blood stasis syndrome is a common syndrome of CSA. Xinnaoning (XNN) capsule is considered as an effective adjuvant treatment for CSA with the efficacy of promoting qi and blood circulation but lack of high-quality clinical evidence. The purpose of this study is to evaluate the efficacy and safety of XNN capsule compared with placebo by clinical trial. METHODS: This multicenter, randomized, double-blind, placebo-controlled trial will be conducted with a total of 240 participants diagnosed with chronic stable angina (qi stagnation and blood stasis syndrome). The participants will be randomized (1:1) into groups receiving either XNN or placebo for 12 weeks. After a 2-week run-in period, they will receive either XNN or placebo (3 pills, 3 times daily) for 12 weeks on the basis of conventional therapy. The primary outcomes include changes in the integral scores of angina symptoms. The secondary outcome measures include changes in the total score of traditional Chinese medicine syndrome, severity grading of angina pectoris, the number of angina pectoris per week, nitroglycerin dosage, score of seattle angina scale, serum homocysteine, incidence of cardiovascular events. Safety outcomes will also be assessed. Adverse events will be monitored throughout the trial. RESULTS: This study will investigate whether XNN capsule can alleviate clinical symptoms, and improve quality of life of patients with chronic stable angina (qi stagnation and blood stasis syndrome). The results of this study will provide clinical evidence for the application of XNN capsule in the treatment of chronic stable angina. TRIAL REGISTRATION: ClinicalTrials.gov: NCT 03914131. |
format | Online Article Text |
id | pubmed-6709279 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-67092792019-10-01 Efficacy and safety of Xinnaoning capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial Zhao, Jun-Nan Zhang, Ying Lan, Xu Chen, Yao Li, Jing Zhang, Ping Wu, Li-Qi Jia, Shu-Ting Liu, Yue Xu, Feng-Qin Medicine (Baltimore) Research Article BACKGROUND: Chronic stable angina (CSA) is a cardiovascular disease with high prevalence. At present, drug treatment is still the main measure of stable angina pectoris. Traditional Chinese medicine has a long history in the treatment of CSA. Qi stagnation and Blood stasis syndrome is a common syndrome of CSA. Xinnaoning (XNN) capsule is considered as an effective adjuvant treatment for CSA with the efficacy of promoting qi and blood circulation but lack of high-quality clinical evidence. The purpose of this study is to evaluate the efficacy and safety of XNN capsule compared with placebo by clinical trial. METHODS: This multicenter, randomized, double-blind, placebo-controlled trial will be conducted with a total of 240 participants diagnosed with chronic stable angina (qi stagnation and blood stasis syndrome). The participants will be randomized (1:1) into groups receiving either XNN or placebo for 12 weeks. After a 2-week run-in period, they will receive either XNN or placebo (3 pills, 3 times daily) for 12 weeks on the basis of conventional therapy. The primary outcomes include changes in the integral scores of angina symptoms. The secondary outcome measures include changes in the total score of traditional Chinese medicine syndrome, severity grading of angina pectoris, the number of angina pectoris per week, nitroglycerin dosage, score of seattle angina scale, serum homocysteine, incidence of cardiovascular events. Safety outcomes will also be assessed. Adverse events will be monitored throughout the trial. RESULTS: This study will investigate whether XNN capsule can alleviate clinical symptoms, and improve quality of life of patients with chronic stable angina (qi stagnation and blood stasis syndrome). The results of this study will provide clinical evidence for the application of XNN capsule in the treatment of chronic stable angina. TRIAL REGISTRATION: ClinicalTrials.gov: NCT 03914131. Wolters Kluwer Health 2019-08-02 /pmc/articles/PMC6709279/ /pubmed/31374015 http://dx.doi.org/10.1097/MD.0000000000016539 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | Research Article Zhao, Jun-Nan Zhang, Ying Lan, Xu Chen, Yao Li, Jing Zhang, Ping Wu, Li-Qi Jia, Shu-Ting Liu, Yue Xu, Feng-Qin Efficacy and safety of Xinnaoning capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial |
title | Efficacy and safety of Xinnaoning capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial |
title_full | Efficacy and safety of Xinnaoning capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial |
title_fullStr | Efficacy and safety of Xinnaoning capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial |
title_full_unstemmed | Efficacy and safety of Xinnaoning capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial |
title_short | Efficacy and safety of Xinnaoning capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial |
title_sort | efficacy and safety of xinnaoning capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): study protocol for a multicenter, randomized, double-blind, placebo-controlled trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709279/ https://www.ncbi.nlm.nih.gov/pubmed/31374015 http://dx.doi.org/10.1097/MD.0000000000016539 |
work_keys_str_mv | AT zhaojunnan efficacyandsafetyofxinnaoningcapsuleintreatingchronicstableanginaqistagnationandbloodstasissyndromestudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT zhangying efficacyandsafetyofxinnaoningcapsuleintreatingchronicstableanginaqistagnationandbloodstasissyndromestudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT lanxu efficacyandsafetyofxinnaoningcapsuleintreatingchronicstableanginaqistagnationandbloodstasissyndromestudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT chenyao efficacyandsafetyofxinnaoningcapsuleintreatingchronicstableanginaqistagnationandbloodstasissyndromestudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT lijing efficacyandsafetyofxinnaoningcapsuleintreatingchronicstableanginaqistagnationandbloodstasissyndromestudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT zhangping efficacyandsafetyofxinnaoningcapsuleintreatingchronicstableanginaqistagnationandbloodstasissyndromestudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT wuliqi efficacyandsafetyofxinnaoningcapsuleintreatingchronicstableanginaqistagnationandbloodstasissyndromestudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT jiashuting efficacyandsafetyofxinnaoningcapsuleintreatingchronicstableanginaqistagnationandbloodstasissyndromestudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT liuyue efficacyandsafetyofxinnaoningcapsuleintreatingchronicstableanginaqistagnationandbloodstasissyndromestudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial AT xufengqin efficacyandsafetyofxinnaoningcapsuleintreatingchronicstableanginaqistagnationandbloodstasissyndromestudyprotocolforamulticenterrandomizeddoubleblindplacebocontrolledtrial |